Having trouble accessing articles? Reset your cache.

Bristol-Myers to acquire ZymoGenetics

Bristol-Myers Squibb Co. (NYSE:BMY) plans to acquire partner ZymoGenetics Inc. (NASDAQ:ZGEN) in a tender offer of $9.75 per share, or about $885

Read the full 226 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE